A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
about
The influence of subclonal resistance mutations on targeted cancer therapyCancer heterogeneity--a multifaceted viewDevelopment of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitorsClinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib eraDose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer PatientsSystematic assessment of analytical methods for drug sensitivity prediction from cancer cell line dataNovel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylatePreexistence and clonal selection of MET amplification in EGFR mutant NSCLC.Using functional genomics to overcome therapeutic resistance in hematological malignancies.Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors.Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsMonitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.Eosinophilia: secondary, clonal and idiopathic.Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction.When (distant) relatives stay too long: implications for cancer medicine.The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisBCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Implications of intratumour heterogeneity for treatment stratification.Intratumoral functional heterogeneity and chemotherapyRottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.Cancer stem cells as 'units of selection'.The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer.The significance of intertumor and intratumor heterogeneity in liver cancer.Coherent feedforward transcriptional regulatory motifs enhance drug resistance.Modeling the Subclonal Evolution of Cancer Cell Populations.Calculated resistance in cancer.
P2860
Q26781693-BDEB035E-0D42-450B-B512-37743E082643Q26829228-22D1A79A-3496-4F41-A552-8EC11478E5FDQ27302811-5DC2A4EC-9AF7-4E22-AE6E-96F1FC6E44BCQ27851527-7F48AF85-2916-4949-9AD9-38778BD2774EQ27851628-A99E1FCB-C3A3-4001-B2DB-A4E3398BBB70Q28486093-0F73C4A7-0E6D-46EC-80B1-3034422B9B93Q28550661-1E7D1A5D-F3F3-4205-B822-4DFD6CDF799EQ30705777-77F704CE-5619-4FF7-A756-10262CE1EBD9Q33847866-A538D3FE-C62A-4137-9ECB-9BA1581CA692Q34184723-C9A856F6-B06B-4F11-97F9-E9ED00A1325FQ34307548-5575C997-A54D-44AE-9136-EC92BD6AA272Q34401328-EA9FB9F0-E002-4460-A888-B31A144E64FBQ34988221-D793DCE8-620F-49AE-8D01-60A3F4134F1DQ35013457-EB784B66-CAC4-41EA-8942-93DC9394C400Q35071103-98E4E689-790F-4DD5-8FB0-A07FBD823C68Q35221149-25380461-A9CE-4FF3-B9DE-0C880B5C5DC5Q35849776-67770A69-B2CA-402F-9047-C1FA67BA59AFQ36471689-E90B046C-38AE-4400-8601-DAC09CBF8369Q36589648-0BCB20C3-0F09-4275-AA61-7493F896CDDEQ36611947-EED4E756-13E1-48DC-8EE1-B9AB615EBAE1Q37212678-137B4D95-441E-4670-9975-490D92E23CAFQ37974490-A0264C25-89B9-41D3-95CD-259CA670B0A4Q38151633-17801A0B-03D6-424B-B387-641C18BECB96Q38195832-10895A8F-9AB5-4CED-86BF-8BBB13DACA72Q40203788-1E17FF19-FE44-4A01-960E-E4E9E990BB2EQ42108136-804A4078-B1E9-48FA-8F56-92091B5D9B9BQ42805035-B3E403CE-AA9F-4ED0-AB2E-4E1B2FABB204Q46894958-D5CBD4AB-6B4C-47A8-8CFE-CB2B6863A17CQ47750195-BB8CB28A-5658-4908-AA4A-35AE3D378237Q49189286-BFEA9DB3-6C69-432E-99E4-C2F71A89CCCAQ49541273-6F0D4A6D-BBD9-47B8-B1DF-DDA8FAEF1C6CQ53848726-F9C3AE8E-3B28-4146-8F23-1EFE0B4B4D61
P2860
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
A mutation conferring resistan ...... chronic myelogenous leukemia.
@en
A mutation conferring resistan ...... chronic myelogenous leukemia.
@nl
type
label
A mutation conferring resistan ...... chronic myelogenous leukemia.
@en
A mutation conferring resistan ...... chronic myelogenous leukemia.
@nl
prefLabel
A mutation conferring resistan ...... chronic myelogenous leukemia.
@en
A mutation conferring resistan ...... chronic myelogenous leukemia.
@nl
P2093
P356
P1476
A mutation conferring resistan ...... f chronic myelogenous leukemia
@en
P2093
Jean-Luc Laï
Stéphane Darré
Thierry Facon
P304
P356
10.1056/NEJMC035089
P407
P577
2003-05-01T00:00:00Z